



09/965,529

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Lal et al.	Examiner:	Vandervegt, Francois P.
Serial No.:	09/965,529	Group Art Unit:	1644
Filed:	September 26, 2001	Docket No.:	11669.0128USWO
Title:	MEMBRANE ASSOCIATED PROTEINS		

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 408487770 US

Date of Deposit: June 14, 2004

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, Mail Stop Patent Application, P.O. Box 1450, Alexandria, VA 22313-1450.

By:

Name:

Katherine M Kowalechuk
Katherine M Kowalechuk

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(c))

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application. No fee is due as this statement is submitted as certified below under 37 C.F.R. § 1.97(e)(1) or (2) by the undersigned.

Certification Under 37 C.F.R. §1.97(e)(2)

In accordance with 37 C.F.R. §1.97(c) or §1.97(d), the undersigned hereby certifies that no item of information listed on the enclosed Form 1449 was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned after making a reasonable inquiry, no item of information listed on the enclosed Form 1449 was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.


Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903

Date: June 14, 2004

Kathy M Kowalchyk
Kathy M. Kowalchyk
Reg. No. 36,848
KMK:EED:lek



FORM 1449  INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.0128USWO	Application Number: 09/965,529
	Applicant: Lal et al.	
	Filing Date: September 26, 2001	Group Art Unit: 1644

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO03/000113A2	3 Jan. 2003	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Adachi et al., 1998, <i>J. Clin. Oncol.</i> , 16(4):1397-406, Abstract "Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression."
	Shao et al., 2003, <i>Oncogene</i> , 22:5060-5069 "Molecular cloning and characterization of <i>LAPTM4B</i> , a novel gene upregulated in hepatocellular carcinoma."
	Sho et al., 1998, <i>Int. J. Cancer</i> , 79(5):509-16, Abstract "Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer."
	Takagi et al., 1995, <i>Int. J. Cancer</i> , 61(5):706-15, Abstract "Identification of a highly specific surface marker of T-cell acute lymphoblastic leukemia and neuroblastoma as a new member of the transmembrane 4 superfamily."
	<i>The American Heritage Dictionary of the English Language, Third Edition</i> , 3rd ed., Boston, Massachusetts: Houghton Mifflin Company, 1975, p. 1730 Definition of "Specific."
	<i>Websters Ninth New Collegiate Dictionary</i> , 9th ed., Springfield, Massachusetts: Merriam-Webster, Inc., 1983, p. 1132 Definition of "Specific."

23552

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	